Translate this page RSS Share this page Print this page


What Life Sciences Companies Need To Know About The New Miscellaneous Tariff Bill Process

29 Nov 2016, 12:00 PM - 1:00 PM (Eastern Time)                            

The U.S. International Trade Commission ("ITC") has begun accepting petitions seeking temporary duty suspensions and reductions pursuant to the American Manufacturing Competitiveness Act of 2016 ("the Act"). The Act reinstitutes the Miscellaneous Tariff Bill ("MTB") program, which allows Congress to eliminate or reduce duties up to $500,000 per year for a period of up to three years on imported articles not otherwise available in the United States. The deadline for filing petitions is December 12, 2016. The Webinar will:

MTB is a potential opportunity to maximize the value of your company’s procurement function by saving hundreds of thousands of dollars in import duties—per product and for up to three years—on key inputs or other articles that you cannot source in the United States. The Webinar will:

  • Introduce participants to the MTB process, including petition requirements, enhanced transparency procedures, and other key considerations for life sciences companies.
  • Summarize petitions filed to date by life sciences companies.
  • Discuss the Congressional role in crafting MTB legislation based upon petitions filed with the ITC.

You do not have to be a client to attend, and there is no charge.

You can register to attend this webinar by clicking the Register link at the bottom of this page.

General information on our practice is available in our electronic publications Serving the Healthcare Industry, Around the Corner and Serving the Life Sciences Industry. If you would like to be included on our regular pharmaceutical manufacturers, medical device manufacturers or healthcare provider mailing lists to receive notices of other events and written updates, you can be added by submitting your full contact information to and specifying the list you wish to join.

You can also follow us on Twitter or Facebook.


If you have questions concerning this Roundtable Webinar, e-mail